Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2025 EPS estimates for Harmony Biosciences in a research note issued to investors on Monday, July 21st. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.91 per share for the quarter, up from their prior estimate of $0.87. HC Wainwright currently has a "Buy" rating and a $70.00 price objective on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences' Q3 2025 earnings at $0.99 EPS, FY2025 earnings at $3.83 EPS, Q1 2026 earnings at $0.76 EPS, Q2 2026 earnings at $1.01 EPS, Q3 2026 earnings at $1.09 EPS, Q4 2026 earnings at $1.24 EPS, FY2026 earnings at $4.09 EPS and FY2027 earnings at $5.01 EPS.
Several other research firms also recently weighed in on HRMY. Needham & Company LLC restated a "buy" rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday, May 6th. The Goldman Sachs Group upgraded shares of Harmony Biosciences to a "hold" rating and set a $33.00 price target for the company in a research report on Thursday, July 10th. Truist Financial initiated coverage on shares of Harmony Biosciences in a research report on Monday. They set a "buy" rating and a $48.00 price target for the company. UBS Group reduced their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Finally, Mizuho upped their price target on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $51.00.
Read Our Latest Stock Analysis on Harmony Biosciences
Harmony Biosciences Price Performance
Shares of Harmony Biosciences stock traded down $0.33 during trading hours on Tuesday, reaching $36.38. The stock had a trading volume of 135,557 shares, compared to its average volume of 664,474. The stock's 50 day moving average is $34.01 and its 200 day moving average is $33.96. The firm has a market capitalization of $2.09 billion, a PE ratio of 13.90, a PEG ratio of 0.51 and a beta of 0.83. Harmony Biosciences has a twelve month low of $26.47 and a twelve month high of $41.61. The company has a current ratio of 3.67, a quick ratio of 3.63 and a debt-to-equity ratio of 0.22.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.59 by $0.19. The business had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 20.53% and a return on equity of 24.32%. The company's revenue was up 19.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 earnings per share.
Institutional Trading of Harmony Biosciences
A number of hedge funds have recently bought and sold shares of HRMY. Deep Track Capital LP purchased a new stake in shares of Harmony Biosciences during the 4th quarter valued at approximately $49,894,000. Vanguard Group Inc. raised its position in shares of Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after buying an additional 1,262,362 shares during the period. Marshall Wace LLP raised its position in shares of Harmony Biosciences by 165.2% during the 4th quarter. Marshall Wace LLP now owns 929,744 shares of the company's stock valued at $31,992,000 after buying an additional 579,103 shares during the period. New Vernon Capital Holdings II LLC raised its position in shares of Harmony Biosciences by 3,219.0% during the 1st quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company's stock valued at $16,211,000 after buying an additional 473,708 shares during the period. Finally, Norges Bank purchased a new stake in shares of Harmony Biosciences during the 4th quarter valued at approximately $16,118,000. Institutional investors and hedge funds own 86.23% of the company's stock.
Harmony Biosciences Company Profile
(
Get Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Recommended Stories
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
